MDX-1342 Antibody is a research-grade biosimilar monoclonal antibody targeting CD19. It is a human IgG1-Kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi).
Product Name:
MDX-1342 Antibody
SKU:
GXBS00837
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
B-lymphocyte antigen CD19
Isotype:
IgG1-Kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
1646327-65-2
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
